• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients

Objective: to improve access to diagnosis, and to treat people affected by this disease.

Home > Press releases

DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients

Objective: to improve access to diagnosis, and to treat people affected by this disease.

Women being tested for Chagas in Colombia
Bogotá, Colombia — 14 Apr 2018

An agreement to facilitate and strengthen access to diagnosis and treatment of patients with Chagas and other diseases of public health interest has been signed by the Colombian Ministry of Health and Social Protection and the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi).

The agreement, signed during the celebration of World Chagas Day, concerns the development of a pilot programme for validation of the Roadmap of care for Chagas disease, currently under way in four departments (or states) of Colombia. The partnership also includes the implementation of a new diagnostic system developed by the Colombian National Institute of Health (INS), which recently published a new public health surveillance protocol to guide actors in the health system in providing comprehensive care for Chagas patients.

As a part of the partnership, Colombia has already achieved increases of 1,455% and 1,129% in the number of patients obtaining access to Chagas diagnosis in the municipalities of Támara and Nunchía, (Casanare department), respectively. The results are part of the Pilot Project to Eliminate Barriers to Access for Chagas Patients that has just completed its first year. The project has also made major strides in the municipality of Soatá (Boyacá). Once validated, the Chagas Roadmap will be extended to the rest of the country.

In addition to these important strides in patient care, the Ministry of Health has taken measures through the plan for interruption of household transmission by the main Chagas vector (known in English as “kissing bug” and locally as “pito”). The goal for 2021 is to have 106 municipalities certified as household transmission-free. At present, 33 municipalities have been certified by the Pan American Health Organization (PAHO).

The INS has also done outstanding work through the National Program for the Prevention, Control, and Treatment of Chagas Disease, which convenes research groups, academic institutions, and civil society to achieve results that will back decision-making in public health and serve as evidence for patient care protocols, in addition to the Network for Knowledge Management, Research, and Innovation in Chagas Disease, designed as the framework for research in this parasitic disease to help meet the goals of the Ten-Year Public Health Plan for 2012-2021.

About Chagas

According to the World Health Organization (WHO), Chagas disease affects more than six million persons worldwide, most of whom in Latin America. In Colombia, approximately 4,800,000 persons are at risk of infection, of whom 438,000 are infected, with an estimated 5,274 new cases every year. Of these, according to reports by the Colombian National Institute of Health, fewer than 1,000 are receiving treatment.

According to data from the Ministry of Health and Social Protection, an average of 25 cases in the acute phase and 1,000 cases in the chronic phase are diagnosed per year in Colombia. The WHO estimates 131,388 cases of Chagas cardiopathy in Colombia.

Chagas is a silent disease caused by infection with the parasite Trypanosoma cruzi, transmitted mainly by contact with fecal matter of infected kissing bugs or pitos (the insect vector). Approximately 30% of persons that are infected go on to develop the disease. The most frequently affected organs are the heart and to a lesser extent the digestive tract, especially the colon and/or esophagus.

Read more information on Chagas disease


Visual story

Ending the neglect of Chagas in Colombia

Bringing Chagas disease care to a remote Colombian region

Photo credit: Felipe Abondano-DNDi

Partnership Registration & access Chagas disease

Read, watch, share

Loading...
Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

Press releases
15 Apr 2025

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License